The EXCLAIM study: Extended thromboprophylaxis with enoxaparin in acutely ill medical patients with restricted mobility.

被引：0
|
作者：
Hull, R
Tapson, VF
Schellong, S
Yusen, RD
Monreal, M
Samama, MM
Turpie, AGG
Wildgoose, P
Cort, S
机构：
[1] Univ Calgary, Foothills Hosp, Calgary, AB T2N 1N4, Canada
[2] Duke Univ, Med Ctr, Durham, NC 27706 USA
[3] Universitatsklinikum Carl Gustav Carus, Med Klin & Poliklin 3, Dresden, Germany
[4] Washington Univ, Sch Med, St Louis, MO 63130 USA
[5] Hosp Germans Trias & Pujol, Barcelona, Spain
[6] Serv Hematol Biol, Paris, France
[7] McMaster Univ, HHSC McMaster Clin, Hamilton, ON L8S 4L8, Canada
[8] Aventis Pharma, Bridgewater, NJ USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4208
引用
收藏
页码：125B / 125B
页数：1
相关论文
共 50 条
  • [31] Effectiveness of an Admission Proforma in Improving Prescription of Thromboprophylaxis in Acutely ill Medical Patients
    McMahon, D.
    Kelly, T.
    Saies, A.
    Spence, C.
    Watts, M.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : S219 - S220
  • [32] Thromboprophylaxis in Acutely Ill Medical Patients: Results of A Survey Among Italian Physicians
    Dentali, Francesco
    Pomero, Fulvio
    La Regina, Micaela
    Orlandini, Francesco
    Turato, Sara
    Mazzone, Antonino
    Nozzoli, Carlo
    Fontanella, Andrea
    Ageno, Walter
    Agnelli, Giancarlo
    Campanini, Mauro
    THROMBOSIS RESEARCH, 2014, 134 (03) : 572 - 577
  • [33] Consistent venous thromboembolism risk reduction by extended-versus standard-duration enoxapaiin prophylaxis in subgroups of acutely ill medical patients in the EXCLAIM study
    Tapson, Victor F.
    Hull, Russell D.
    Schellong, Sebastian M.
    Monreal, Manuel
    Samama, Meyer-Michel
    Turpie, Alexander G. G.
    Yusen, Roger D.
    BLOOD, 2007, 110 (11) : 552A - 552A
  • [34] Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients
    Robin Offord
    Adam C. Lloyd
    Pippa Anderson
    Andy Bearne
    Pharmacy World and Science, 2004, 26 : 214 - 220
  • [35] Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients
    Offord, R
    Lloyd, AC
    Anderson, P
    Bearne, A
    PHARMACY WORLD & SCIENCE, 2004, 26 (04): : 214 - 220
  • [36] A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
    Samama, MM
    Cohen, AT
    Darmon, JY
    Desjardins, L
    Eldor, A
    Janbon, C
    Leizorovicz, A
    Nguyen, H
    Olsson, CG
    Turpie, AG
    Weisslinger, N
    NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11): : 793 - 800
  • [37] Updates on the Risk of Dalteparin Thromboprophylaxis Failure in Hospitalized Acutely Ill Medical Patients with Cancer (ARTIC STUDY)
    Louzada, Martha L.
    Al-Ani, Fatimah
    Kovacs, Michael J.
    Siqueira, Lenicio
    Lazo-Langner, Alejandro
    BLOOD, 2015, 126 (23)
  • [38] Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients
    Goldhaber, Samuel Z.
    Leizorovicz, Alain
    Kakkar, Ajay K.
    Haas, Sylvia K.
    Merli, Geno
    Knabb, Robert M.
    Weitz, Jeffrey I.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (23): : 2167 - 2177
  • [39] Rivaroxaban Compared with Enoxaparin for the Prevention of Venous Thromboembolism In Acutely Ill Medical Patients: MAGELLAN Study Methodology
    Cohen, Alexander Thomas
    Spiro, Theodore Erich
    Buller, Harry Roger
    Haskell, Lloyd
    Hu, Da-Yi
    Hull, Russell
    Mebazaa, Alexandre
    Merli, Geno
    Schellong, Sebastian
    Spyropoulos, Alexander
    Tapson, Victor
    BLOOD, 2010, 116 (21) : 1364 - 1364
  • [40] Thromboprophylaxis with dalteparin for the prevention of venous thromboembolism in acutely ill medical patients with respiratory failure
    Cohen, AT
    Leizorovicz, A
    Turpie, AG
    Olsson, CG
    Vaitkus, PT
    Goldhaber, SZ
    CHEST, 2003, 124 (04) : 132S - 133S
12345